Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Plus Chemotherapy in R/R ETP-ALL
NCT03613428Phase 2Unknown
- Sponsor
- Sichuan University
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of ruxolitinib in early T-cell precursor acute lymphoblastic leukemia (ETP-ALL), sponsored by Sichuan University. Status: unknown.
02
Drugs
03
Conditions
early T-cell precursor acute lymphoblastic leukemia (ETP-ALL)
Beyond the preview
Go deeper on NCT03613428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03613428.